PANTOPRAZOLE SODIUM (pantoprazole) by Hetero is (h , k )-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for older for the short-term treatment (up to 8 weeks) in the healing, symptomatic relief of erosive esophagitis (ee). First approved in 2014.
Drug data last refreshed 18h ago
(H , K )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H , K )-ATPase results in a duration of antisecretory effect that persists…
Worked on PANTOPRAZOLE SODIUM at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy
Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions